FDA Grants Traditional Approval for Fabhalta to Slow Kidney Function Decline in Adults with IgAN

Novartis announced that the U.S. Food and Drug Administration (FDA) has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease progression. Fabhalta, a first-in-class complement inhibitor, received this approval under a priority review designation, building on an initial accelerated approval in August 2024 for reducing proteinuria in primary IgAN. Clinical data showed Fabhalta significantly slowed the decline in estimated glomerular filtration rate (eGFR) over two years and demonstrated clinically meaningful improvements in protein in urine.

Context

IgAN is a common form of kidney disease characterized by the buildup of immunoglobulin A in the kidneys, leading to inflammation and damage. Prior to this approval, treatment options were limited, and patients often faced a poor prognosis as the disease progressed. Fabhalta, developed by Novartis, is the first complement inhibitor approved for this condition, following an accelerated approval that focused on reducing proteinuria.

Why it matters

The FDA's traditional approval of Fabhalta marks a significant advancement in treatment options for adults with IgAN, a kidney disease that can lead to severe health complications. This approval reflects the importance of addressing chronic kidney conditions and offers hope to patients at risk of disease progression. Slowing kidney function decline can improve quality of life and reduce the need for more invasive treatments like dialysis or transplantation.

Implications

The approval of Fabhalta could lead to improved management of IgAN, potentially reducing the burden on healthcare systems associated with advanced kidney disease. Patients may experience better health outcomes and quality of life, while healthcare providers will have a new tool to combat this challenging condition. This development may also influence future research and investment in treatments for other kidney diseases.

What to watch

As Fabhalta becomes available, healthcare providers will monitor its integration into treatment protocols for IgAN. Patient outcomes and long-term effects of the drug will be closely observed in clinical settings. Additionally, Novartis may seek to expand research on Fabhalta's efficacy in other kidney-related conditions.